|
| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Jan 12 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Sanofi Bets $2.56B on Next-Gen Bispecific Antibodies with Earendil Labs
|
|
| | Amgen Strengthens Oncology Pipeline with $840M Dark Blue Therapeutics Acquisition
|
|
| | Ikarovec Targets Billion-Dollar Gene Therapy Potential in Intermediate AMD
|
|
| | MediLink & Roche Double Down on B7-H3 ADC with $570M Oncology Deal
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Top Stories This Week
|
| |
| • | Sanofi Bets $2.56B on Next-Gen Bispecific Antibodies with Earendil Labs
|
|
| • | Amgen Strengthens Oncology Pipeline with $840M Dark Blue Therapeutics Acquisition
|
|
| • | Ikarovec Targets a Billion-Dollar Gene Therapy Opportunity in Intermediate AMD
|
|
| • | MediLink & Roche Double Down on Oncology with a $570M B7-H3 ADC Deal
|
|
| |
Cover Story
|
| |
Lilly Goes All-In:
|
| |
| • | $3.45B Fueling the Future of Medicine
|
|
| • | Inflammation: $1.2B Acquisition of Ventyx
|
|
| • | Oncology: $950M AI-Driven Collaboration with InduPro
|
|
| • | Metabolic Diseases: $1.3B+ Obesity Deal with Nimbus
|
|
| |
Strategic M&A & Partnerships
|
| |
| • | Amgen’s $840M Oncology Discovery Push
|
|
| • | Sanofi–Earendil: A $2.56B Bispecific Antibody Play
|
|
| • | Insilico–Servier: Scaling AI-Driven Oncology Discovery
|
|
| • | Pfizer–Cartography: Mapping Tumor-Selective Targets
|
|
| • | Pierre Fabre–Iktos: AI-Designed Oncology Drugs
|
|
| • | Foresee–Primevera: Global MMP-12 Licensing Deal
|
|
| • | MediLink–Roche: Expanding the B7-H3 ADC Alliance
|
|
| |
Clinical Trial Highlights
|
| |
|
| ○ | Pancreatic Cancer (HUTCHMED | P-II/III)
|
|
| ○ | DLBCL (Incyte | frontMIND P-III)
|
|
| ○ | HER2+ GEA (Jazz Pharma | HERIZON-GEA-01 P-III)
|
|
| ○ | KRAS G12C NSCLC (Merck | KANDLELIT-007 P-III)
|
|
|
| ○ | Lupus / SLE (J&J | JASMINE P-IIb)
|
|
| ○ | Psoriatic Arthritis + Obesity (Lilly | TOGETHER-PsA P-IIIb)
|
|
| • | Cardio-Metabolic & Infectious Diseases
|
|
| ○ | Atrial Fibrillation (Acesion Pharma | P-II)
|
|
| ○ | Chronic Hepatitis B (GSK | B-Well 1/2 P-III)
|
|
| |
Global Regulatory Momentum
|
| |
| • | Arrowhead: NMPA & Health Canada Approval for Redemplo
|
|
| • | Ascletis: US FDA IND Clearance for ASC30 (T2D)
|
|
| • | GSK: Nucala (COPD) & Exdensur (Asthma, CRSwNP)
|
|
| • | Sanofi: FDA Priority Review for Tzield (Pediatric T1D)
|
|
| • | Takeda–Protagonist: NDA Submission for Rusfertide
|
|
| • | Annexon: EU Filing for Tanruprubart (GBS)
|
|
| |
MedTech Milestones
|
| |
| • | RefleXion Medical: FDA Clearance for RefleXion X2 (Oncology Precision)
|
|
| • | Saluda Medical: CE Mark for EVA Sensing Technology (Personalized Pain Management)
|
|
| |
Market Access & Biosimilars
|
| |
| • | Otulfi Launch: Fresenius Kabi Brings an Interchangeable Stelara Biosimilar to Market
|
|
| |
PharmaShots Perspective
|
| |
| • | Precision, Platforms, and Pipeline Power:
What Early 2026 Tells Us About Biopharma’s Strategic Direction
|
|
| |
Stay Ahead with PharmaShots Weekly
|
| |
| • | Why Leaders Choose PharmaShots
|
|
| • | Subscribe • Share • Stay Informed
|
|
| |
|
| |
|
| |
Lilly Goes All-In – $3.45B Fueling the Future of Medicine
|
| |
|
| |
Eli Lilly is making strategic waves across three high-impact fronts, signaling a bold commitment to next-generation therapies and platform-driven innovation. With a combined investment of $3.45B, Lilly is reshaping its pipeline across inflammation, oncology, and metabolic diseases, aiming to deliver transformative therapies where patient needs are greatest.
|
| |
Inflammation – $1.2B Acquisition of Ventyx
Lilly strengthens its immunology portfolio with Ventyx, gaining oral NLRP3 inhibitors targeting cardiometabolic, neurodegenerative, and autoimmune diseases. This move expands Lilly’s capabilities in inflammation-driven conditions, adding cutting-edge assets to its next-gen pipeline.
|
| |
Oncology – $950M Collaboration with InduPro
Leveraging AI/ML-enabled MInt technology, Lilly partners with InduPro to accelerate discovery of bispecific and multispecific antibodies. This strategic alliance enhances precision oncology, bringing targeted therapies from concept to clinic faster and more efficiently.
|
| |
Metabolic Diseases – $1.3B+ Deal with Nimbus
Building on prior AMPK work, Lilly and Nimbus advance a novel oral obesity therapy using computational chemistry and structure-based design. The program, valued at $1.3B in milestones, reinforces Lilly’s leadership in metabolic innovation and addresses a major unmet patient need.
Lilly’s multi-pronged strategy is bold and calculated, blending acquisitions, AI-driven discovery, and platform innovation. By simultaneously targeting inflammation, oncology, and metabolic diseases, Lilly is positioning itself to capture high-value patient populations, accelerate pipeline momentum, and define the next era of transformative therapies.
|
| |
|
| |
| | Amgen Doubles Down on Oncology Discovery with an $840M Strategic Buy
|
|
|
|
|
| |
Amgen Strengthens Its Oncology Discovery Engine with $840M Strategic Acquisition
|
| |
|
| |
Doubling Down on Early-Stage Cancer Innovation
|
| |
Amgen acquires Dark Blue Therapeutics for approximately $840 million, sharpening its early-stage oncology discovery and bolstering its research pipeline. The deal fully integrates Dark Blue into Amgen’s research organization, speeding the translation of cutting-edge science into next-generation cancer therapies.
|
| |
Why This Acquisition Matters
This strategic buy centers on a preclinical small-molecule degrader targeting MLLT1/3 for select acute myeloid leukemia (AML) subtypes, with differentiated anti-cancer activity to tackle resistance:
|
| |
| • | Key asset: Preclinical MLLT1/3 degrader for AML, potent as monotherapy or combination.
|
|
| • | Pipeline integration: Enhances Amgen’s oncology research depth.
|
|
| • | Deal value: $840 million acquisition.
|
|
| • | Strategic impact: Accelerates resistance-overcoming therapies.
|
|
| |
A Strategic Step Forward
For Amgen, the acquisition fortifies its oncology leadership by adding high-potential degraders to its arsenal. It sets the stage for innovative AML treatments, bridging discovery to clinical impact for patients.
|
| |
Ikarovec Eyes a Billion-Dollar Gene Therapy Opportunity in Intermediate AMD
|
| |
Unlocking Office-Based Delivery for Vision Preservation
Ikarovec inks an exclusive worldwide option agreement with VectorBuilder for its AAV capsid technology, propelling lead candidate IKAR-003 toward intermediate age-related macular degeneration (AMD). Upon successful evaluation, Ikarovec takes over clinical development and commercialization, with the deal potentially exceeding $1 billion.
|
| |
Why This Partnership Matters
The collaboration leverages VectorBuilder’s next-generation AAV capsids for office-based intravitreal delivery of IKAR-003—a one-time gene therapy combining neuroprotection and complement modulation to halt AMD progression:
|
| |
| • | Core asset: IKAR-003 for intermediate AMD, enabling broader patient access.
|
|
| • | Delivery innovation: Office-based AAV intravitreal administration.
|
|
| • | Deal potential: Over $1 billion in value tied to program milestones.
|
|
| • | Therapeutic goal: Preserve vision by stopping disease advancement.
|
|
| |
A Strategic Step Forward
For Ikarovec, this option validates IKAR-003’s billion-dollar potential in AMD. Paired with VectorBuilder’s capsid tech, it positions the therapy for scalable, one-time treatment—transforming access and outcomes for intermediate AMD patients.
|
| |
Insilico and Servier Join Forces to Accelerate AI-Driven Oncology Discovery
|
| |
Harnessing Pharma.AI for Hard-to-Treat Cancer Targets
Insilico Medicine enters a multi-year R&D collaboration with Servier to discover next-generation oncology therapeutics for hard-to-drug targets using the Pharma.AI platform. Servier co-funds efforts and leads clinical validation, regulatory filings, and global commercialization of selected assets.
|
| |
Why This Collaboration Matters
The partnership accelerates AI-driven oncology innovation, with Insilico’s platform unlocking novel candidates:
|
| |
| • | Target focus: Hard-to-drug oncology targets via Pharma.AI.
|
|
| • | Role split: Insilico handles discovery; Servier drives clinical and commercial stages.
|
|
| • | Financials: $32 million upfront/near-term payments; up to $888 million total value.
|
|
| • | Impact: Scales AI to deliver breakthrough cancer therapies.
|
|
| |
A Strategic Step Forward
For Insilico, the deal affirms Pharma.AI’s prowess in oncology. For Servier, it bolsters its pipeline with AI-sourced assets. Together, they pioneer efficient paths from target to patient, transforming hard-to-drug cancers.
|
| |
Sanofi Taps Earendil Labs in a $2.56B Bispecific Antibody Bet
|
| |
Targeting Autoimmune Diseases with Next-Gen Precision
Sanofi enters a strategic collaboration with Earendil Labs to discover and develop bispecific antibody therapies for autoimmune and inflammatory diseases, powered by Earendil’s proprietary platform. Earendil leads candidate identification and optimization; Sanofi handles development and global commercialization.
|
| |
Why This Collaboration Matters
The alliance fuses Earendil’s discovery engine with Sanofi’s execution strength for high-impact bispecifics:
|
| |
| • | Focus areas: Autoimmune and inflammatory targets.
|
|
| • | Divided roles: Earendil on discovery/optimization; Sanofi on clinical/commercial.
|
|
| • | Deal value: $160 million upfront/near-term; up to $2.56 billion total, plus low double-digit royalties.
|
|
| • | Upside: Tiered royalties on net sales for sustained value.
|
|
| |
A Strategic Step Forward
For Sanofi, this bolsters its immunology portfolio with cutting-edge bispecifics. For Earendil, it validates its platform on a global scale. Together, they accelerate therapies to meet urgent patient needs in autoimmunity.
|
| |
Pfizer Partners with Cartography to Map the Next Frontier of Tumor-Selective Targets
|
| |
Mapping Precision Targets with ATLAS and SUMMIT Platforms
Pfizer enters a strategic multi-year collaboration with Cartography Biosciences to discover and validate tumor-selective antigens using the ATLAS and SUMMIT platforms. Cartography leads discovery/validation in an undisclosed cancer indication; Pfizer gains opt-in rights for advancement, while Cartography retains ownership of lead asset CBI-1214.
|
| |
Why This Collaboration Matters
The partnership unlocks next-gen precision oncology through tumor-selective targets:
|
| |
| • | Core platforms: Cartography’s ATLAS for antigen discovery and SUMMIT for validation.
|
|
| • | Rights structure: Pfizer opt-ins post-validation; Cartography keeps CBI-1214 independence.
|
|
| • | Financials: $65 million upfront/near-term/option fees; up to $800 million in milestones, plus tiered royalties.
|
|
| • | Focus: Undisclosed cancer with tumor-selective potential.
|
|
| |
A Strategic Step Forward
For Pfizer, this enhances its oncology precision toolkit. For Cartography, it funds platform expansion while safeguarding key assets. Together, they chart tumor-selective therapies for superior safety and efficacy.
|
| |
|
| |
| | Licensing, Alliances, and AI: Strategic Deals Reshaping Oncology and Inflammatory Drug Discovery
|
|
|
|
|
| |
|
| |
Foresee and Primevera Strike a Global MMP-12 Licensing Deal Spanning Asthma and Rare Diseases
|
| |
Advancing Inhibitors for Inflammatory and Rare Diseases
Foresee Biosciences grants Primevera an exclusive global license for its MMP-12 inhibitor portfolio, including FP-025, FP-020, and third-generation discovery assets. Primevera fully funds development, with FP-020 eyeing an early 2026 IND for Phase II asthma and FP-025 advancing to Phase II in rare diseases.
|
| |
Why This Licensing Deal Matters
The agreement positions MMP-12 inhibitors for broad inflammatory applications:
|
| |
| • | Portfolio scope: FP-025 (rare diseases), FP-020 (asthma Phase II), and next-gen inhibitors.
|
|
| • | Financials: $10 million upfront; up to $574.5 million milestones; tiered single-digit royalties (or sublicense share option); 19% Primevera equity.
|
|
| • | Development: Primevera funds all ongoing/future work.
|
|
| • | Timelines: FP-020 IND in early 2026; FP-025 Phase II initiation.
|
|
| |
A Strategic Step Forward
For Foresee, this provides non-dilutive funding and equity upside while retaining alignment. For Primevera, it captures a differentiated pipeline in inflammation. Together, they accelerate MMP-12 therapies to patients.
|
| |
|
| |
MediLink and Roche Deepen Oncology Alliance with a $570M Bet on a B7-H3 ADC
|
| |
Targeting Solid Tumors with YL201 Antibody-Drug Conjugate
|
| |
MediLink deepens its oncology alliance with Roche through an expanded collaboration and exclusive licensing agreement for YL201, a B7-H3-targeting ADC across solid tumor indications. Roche gains worldwide rights outside Mainland China, Hong Kong SAR, and Macau SAR for development, manufacturing, and commercialization.
|
| |
Why This Collaboration Matters
The deal accelerates YL201’s global potential in solid tumors:
|
| |
| • | Key asset: YL201 B7-H3 ADC for broad solid tumor applications.
|
|
| • | Territorial split: Roche ex-China rights; MediLink retains Greater China.
|
|
| • | Financials: $570 million upfront/near-term milestones; further milestones plus tiered royalties on ex-China sales.
|
|
| • | Expertise synergy: Roche’s oncology infrastructure speeds advancement.
|
|
| |
A Strategic Step Forward
For MediLink, this validates YL201 and funds expansion. For Roche, it enriches its ADC portfolio. Together, they position the B7-H3 ADC for transformative impact in solid tumor therapy.
|
| |
|
| |
Pierre Fabre and Iktos Unite to Fast-Track AI-Designed Oncology Drugs
|
| |
Blending Generative AI with Disease Expertise
|
| |
Pierre Fabre Laboratories teams up with Iktos in an integrated drug discovery collaboration to develop novel small-molecule oncology therapies. Iktos applies its AI-driven generative design platform to create and optimize candidates against an undisclosed target; Pierre Fabre provides oncology and preclinical guidance for advancement.
|
| |
Why This Collaboration Matters
The alliance fuses AI speed with therapeutic insight for oncology breakthroughs:
|
| |
| • | AI core: Iktos’ generative platform for rapid small-molecule design/optimization.
|
|
| • | Expertise split: Pierre Fabre leads target selection, evaluation, and preclinical progression.
|
|
| • | Financial structure: Undisclosed upfront plus multiple milestone payments.
|
|
| • | Target: Undisclosed oncology indication.
|
|
| |
A Strategic Step Forward
For Pierre Fabre, this injects AI efficiency into its oncology pipeline. For Iktos, it showcases generative AI in real-world discovery. Together, they hasten next-gen cancer drugs from concept to clinic.
|
| |
|
| |
| | Key Phase II–III Trial Highlights Across Oncology, Autoimmune, and Cardiovascular Diseases
|
|
|
|
|
| |
P-II/III Trial by HUTCHMED
|
| |
|
| |
Pancreatic Cancer
|
| |
Highlights from the P-II/III Trial by HUTCHMED
|
| |
HUTCHMED has initiated the Phase III portion of its Phase II/III trial evaluating the quadruple combination of surufatinib + camrelizumab + nab-paclitaxel + gemcitabine (S+C+AG) as first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) in China. The first patient was dosed on December 30, 2025, advancing options for this aggressive oncology indication.
|
| |
Key Outcomes from Phase II (n=62)
|
| |
| • | Median PFS: 7.20 months (S+C+AG) vs 5.52 months (AG alone); 50.1% risk reduction
|
|
|
|
| • | Favorable OS trend (not reached vs 8.48 months, immature data)
|
|
| |
Trial Design (Phase III)
~400 treatment-naïve adult PDAC patients; S+C+AG vs nab-paclitaxel + gemcitabine. Primary endpoint: OS. Secondary: PFS, ORR, DoR, DCR, QoL, safety.
|
| |
What’s Next
Phase III enrollment underway, positioning S+C+AG as a potential new frontline standard in metastatic PDAC.
|
| |
|
| |
DLBCL
|
| |
Highlights from the P-III frontMIND by Incyte
Incyte reported positive topline results from the Phase III frontMIND trial of Monjuvi (tafasitamab) + lenalidomide + R-CHOP vs R-CHOP alone as first-line treatment in ~900 adults with previously untreated diffuse large B-cell lymphoma (DLBCL), including high-risk patients (IPI 3–5 if >60 years; aaIPI 2–3 if ≤60 years).
|
| |
Key Outcomes
|
| |
| • | Met primary endpoint: statistically significant PFS improvement (investigator-assessed)
|
|
| • | Met key secondary: improved event-free survival (EFS)
|
|
| |
Regulatory Path Ahead
Incyte plans sBLA submission in H1 2026 for Monjuvi + lenalidomide + R-CHOP in newly diagnosed adult DLBCL patients.
|
| |
What’s Next
Full data presentation at an upcoming medical meeting, positioning the regimen for frontline expansion in high-risk DLBCL.
|
| |
|
| |
Atrial Fibrillation
|
| |
Highlights from the P-II Trial by Acesion Pharma
|
| |
Acesion Pharma has dosed the first patients in a Phase II trial of AP31969 (oral) for atrial fibrillation (AF) across ~200 patients in eight European countries.
|
| |
Key Outcomes from Phase I (n=92 healthy volunteers)
|
| |
| • | Favorable safety profile in single- and multiple-ascending dose cohorts
|
|
| • | Suitable PK for chronic oral dosing
|
|
| • | No clinically meaningful QTc effects, indicating low proarrhythmia risk
|
|
| |
Trial Design
Safety and rhythm outcomes monitored continuously with 24/7 cardiac tracking.
|
| |
What’s Next
Phase II data to support safer AF management options.
|
| |
|
| |
Lupus (SLE)
|
| |
Highlights from the P-IIb JASMINE by Johnson & Johnson
|
| |
Johnson & Johnson reported positive topline results from the Phase IIb JASMINE trial of Imaavy (nipocalimab) vs placebo in 228 adults with systemic lupus erythematosus (SLE). Phase III program now initiated.
|
| |
Key Outcomes
|
| |
| • | Met primary endpoint: higher SRI-4 composite response at Week 24
|
|
| • | Achieved multiple secondary/exploratory endpoints, including steroid-sparing potential
|
|
| |
Mechanism
FcRn monoclonal antibody that lowers pathogenic IgG autoantibodies while preserving immune function.
|
| |
What’s Next
Full data at upcoming congress; Phase III underway for broader autoimmune applications.
|
| |
|
| |
HER2+ Gastroesophageal Adenocarcinoma
|
| |
Highlights from the P-III HERIZON-GEA-01 by Jazz Pharmaceuticals
|
| |
Jazz will present pivotal Phase III results for Ziihera (zanidatamab-hrii) + chemotherapy (CT) ± Tevimbra vs Herceptin + CT in 914 adults with HER2+ locally advanced/metastatic GEA at ASCO 2026.
|
| |
Key Outcomes
|
| |
| • | Median PFS: 12.4 months (both Ziihera arms) vs 8.1 months (control); 35% risk reduction
|
|
| • | Median OS: 24.4 months (Ziihera + CT) and 26.4 months (Ziihera + Tevimbra + CT) vs 19.2 months; 28% risk reduction
|
|
| • | ORR: 70.7% and 69.6% vs 65.7%; DoR: 20.7 and 14.3 vs 8.3 months
|
|
| |
Trial Design
First-line setting; consistent benefits across subgroups.
|
| |
What’s Next
Interim OS analysis mid-2026; potential frontline shift in HER2+ GEA.
|
| |
|
| |
KRAS G12C NSCLC
|
| |
Highlights from the P-III KANDLELIT-007 by Merck
|
| |
Merck initiated the Phase III KANDLELIT-007 trial of calderasib (MK-1084, oral QD) + Keytruda Qlex (subQ Q6W) vs Keytruda Qlex + pemetrexed + CT as first-line therapy in ~675 patients with KRAS G12C-mutant advanced/metastatic nonsquamous NSCLC.
|
| |
Trial Design
Primary endpoint: PFS in PD-L1+ tumors.
|
| |
Pipeline Momentum
|
| |
| • | P-III KANDLELIT-012: calderasib + cetuximab + mFOLFOX6 (KRAS G12C CRC)
|
|
| • | P-III KANDLELIT-004: calderasib + Keytruda (1L KRAS G12C PD-L1+ NSCLC)
|
|
| • | Ongoing P-I/II in other KRAS G12C solid tumors
|
|
| |
What’s Next
Broad Phase III push to expand calderasib across KRAS G12C indications.
|
| |
|
| |
Chronic Hepatitis B
|
| |
Highlights from the P-III B-Well 1/2 by GSK
|
| |
GSK reported positive Phase III results for bepirovirsen vs placebo in >1,800 chronic hepatitis B (CHB) patients across 29 countries.
|
| |
Key Outcomes
|
| |
| • | Met primary endpoint: statistically significant and clinically meaningful functional cure
|
|
| • | Superior to standard of care across all endpoints
|
|
| • | Robust responses in HBsAg ≤1,000 IU/mL subgroup
|
|
| |
Regulatory Path Ahead
Global filings starting Q1 2026.
|
| |
What’s Next
Full data at upcoming congress and peer-reviewed publication.
|
| |
|
| |
Psoriatic Arthritis
|
| |
Highlights from the P-IIIb TOGETHER-PsA by Eli Lilly
|
| |
Lilly reported positive Phase IIIb results from TOGETHER-PsA evaluating Taltz (ixekizumab) + Zepbound (tirzepatide) vs Taltz alone in 271 adults with active psoriatic arthritis (PsA) and obesity/overweight.
|
| |
Key Outcomes
|
| |
| • | Primary: 31.7% achieved ACR50 + ≥10% weight loss vs 0.8% (Taltz alone)
|
|
| • | Key secondary: 64% relative ACR50 increase (33.5% vs 20.4%) at Week 36
|
|
| |
Pipeline Momentum
Ongoing TOGETHER-PsO (PsO + obesity); topline H1 2026.
|
| |
What’s Next
Full data at upcoming meeting; regulatory discussions for dual inflammatory-metabolic approach.
|
| |
|
| |
| | Global Regulatory Momentum: Key Approvals and Submissions in Rare and Chronic Diseases
|
|
|
|
|
| |
From Filings to Approvals: Regulatory Progress Advances Rare and Chronic Care
|
| |
|
| |
The first weeks of 2026 have already seen significant regulatory activity, with multiple approvals, IND clearances, and submissions across rare, metabolic, and respiratory diseases. These milestones highlight the continued pace of innovation and the global push to bring transformative therapies to patients in need.
|
| |
| • | Arrowhead Pharmaceuticals has secured NMPA approval for Redemplo (ploasiran), marking a milestone in the treatment of familial chylomicronemia syndrome (FCS). The therapy also recently received Health Canada approval for the same indication, expanding its global footprint.
|
|
| • | Ascletis Pharma has obtained US FDA IND clearance to initiate a Phase II trial of ASC30 for type 2 diabetes, paving the way for early clinical exploration in metabolic disease.
|
|
| • | GSK continues its regulatory progress with the NMPA approval of Nucala (mepolizumab) for chronic obstructive pulmonary disease (COPD), and the MHLW approval of Exdensur (depemokimab) for severe asthma and CRSwNP, strengthening its respiratory portfolio across key global markets.
|
|
| • | Sanofi has achieved a regulatory milestone with the US FDA granting Priority Review for Tzield, aimed at delaying progression of type 1 diabetes in children aged ≥1 year, underscoring its focus on pediatric metabolic health.
|
|
| • | Takeda and Protagonist Therapeutics have jointly submitted a US FDA NDA for Rusfertide, targeting polycythemia vera, while Annexon is pursuing European approval of Tanruprubart for the treatment of Guillain-Barré syndrome, highlighting continued momentum in rare disease therapeutics.
|
|
| |
|
| |
| | MedTech Milestones: Advancing Precision in Oncology and Pain Management
|
|
|
|
|
| |
Precision at the Forefront: MedTech Innovations in Oncology and Pain Management
|
| |
|
| |
Innovation in medical technology continues to accelerate, bringing smarter diagnostics and personalized therapies closer to patients. Recent regulatory approvals highlight the growing impact of advanced platforms in oncology and pain management.
|
| |
| • | RefleXion Medical has received US FDA clearance for its RefleXion X2 platform, a next-generation system designed to improve tumor detection and enhance precision in cancer care. This milestone underscores the company’s commitment to leveraging advanced imaging and therapy integration for better patient outcomes.
|
|
| • | Saluda Medical has achieved CE Mark approval for its EVA sensing technology, enabling personalized pain management through real-time monitoring and tailored neuromodulation. The approval marks a key step toward broader adoption of precision neuromodulation therapies in Europe.
|
|
| |
|
| |
| | Otulfi Hits the Market: Fresenius Kabi Brings a Stelara Biosimilar to Patients
|
|
|
|
|
| |
Fresenius Kabi Expands Access with Otulfi, a Biosimilar to Stelara
|
| |
|
| |
Fresenius Kabi has officially launched Otulfi, an interchangeable biosimilar to Stelara (ustekinumab), now available in a 45 mg/0.5 mL single-dose vial for subcutaneous (SC) injection.
|
| |
The US FDA granted approval in September 2024, following comprehensive analytical, preclinical, clinical, and manufacturing data demonstrating comparable efficacy, safety, pharmacokinetics, and immunogenicity to Stelara in patients with moderate-to-severe plaque psoriasis.
|
| |
Otulfi has been available since March 2025 in multiple formats: 45 mg/0.5 mL and 90 mg/mL prefilled syringes for SC injection, and a 130 mg/26 mL single-dose vial for intravenous infusion, providing flexible dosing options to meet diverse patient needs.
|
| |
|
| |
| | That’s a Wrap for This Week
We will see you next week
|
|
|
|
|
| |
Precision, Platforms, and Pipeline Power: Biopharma’s Early 2026 Momentum
|
| |
From an industry perspective, the first weeks of 2026 underscore a dynamic acceleration in biopharma innovation and strategic positioning. Eli Lilly’s $1.2B acquisition of Ventyx strengthens its inflammatory disease portfolio, while Amgen’s $840M purchase of Dark Blue Therapeutics signals a renewed focus on early-stage oncology, particularly AML degraders. Partnerships such as Ikarovec–VectorBuilder, Insilico–Servier, and Lilly–Nimbus reflect the growing strategic emphasis on gene therapy, AI-driven discovery, and metabolic disease innovation, with deal values reaching into the billion-dollar range, underscoring the high stakes in next-gen therapeutics. Clinically, pivotal trial readouts—from HUTCHMED’s PDAC quadruple combo to Incyte’s frontMIND in DLBCL and Jazz Pharma’s Ziihera in HER2+ GEA—highlight advancing efficacy signals across oncology, autoimmune, and metabolic indications, while Lilly’s TOGETHER-PsA and GSK’s B-Well programs illustrate the continued momentum in inflammatory and chronic disease treatment. Regulatory activity, including approvals for Arrowhead, GSK, Ascletis, and Fresenius Kabi’s launch of the Stelara biosimilar Otulfi, signals accelerating patient access globally. Taken together, these strategic deals, trial milestones, and regulatory approvals reflect a market increasingly driven by precision, platform-enabled therapies, and high-value partnerships, positioning leading biopharma companies to capture both clinical and commercial advantage.
|
| |
Stay Ahead with PharmaShots Weekly
|
| |
The pharma world moves fast—and so should you. Stay curious, stay informed, and stay ahead with PharmaShots Weekly, your go-to source for pipeline updates, regulatory moves, competitive signals, and strategic shifts—all distilled into minutes, not hours.
|
| |
Join us next Monday at 8 AM EST for insights that matter. If this issue sharpened your thinking, make it a habit. Subscribe today and get PharmaShots Weekly delivered like clockwork—concise, credible, and designed for leaders who don’t have time to chase fragmented news.
|
| |
Know someone in R&D, CI, strategy, or BD who values signal over noise? Forward this along. And if a takeaway hit home, share it on LinkedIn and tag us—we’d love to amplify your perspective.
|
| |
The industry moves fast. You deserve intelligence that moves faster.
|
| |
| | Questions?
Reach out to us [email protected] for any comments, questions, partnership and media inquiry.
|
|
|
|
|
| |
|
0 comments